Literature DB >> 34258797

The hemostatic and thrombotic complications of liver disease.

Hannah Stowe McMurry1, Janice Jou2, Joseph Shatzel3,4.   

Abstract

Hepatic cirrhosis leads to numerous hematologic derangements resulting in a complex and tenuously rebalanced hemostatic milieu. The utility of common hematologic tests including the INR and aPTT in assessing hemostatic and thrombotic risk in patients with cirrhosis is limited, and consensus on transfusion thresholds and proper management of thrombotic complications continues to evolve. This review summarizes the pathophysiology of key derangements of hemostasis including those of platelets, von Willebrand factor, pro- and anticoagulation factors, and fibrin. Additionally, the pathogenesis, consequences, optimal management, and prevention of major thrombotic and bleeding complications in cirrhosis arte discussed.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  blood coagulation; hemostasis; humans; liver cirrhosis; thrombosis

Mesh:

Substances:

Year:  2021        PMID: 34258797      PMCID: PMC9009189          DOI: 10.1111/ejh.13688

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  103 in total

Review 1.  Haemostatic abnormalities in patients with liver disease.

Authors:  Ton Lisman; Frank W G Leebeek; Philip G de Groot
Journal:  J Hepatol       Date:  2002-08       Impact factor: 25.083

2.  Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity.

Authors:  Ton Lisman; Tamara N Bongers; Jelle Adelmeijer; Harry L A Janssen; Moniek P M de Maat; Philip G de Groot; Frank W G Leebeek
Journal:  Hepatology       Date:  2006-07       Impact factor: 17.425

Review 3.  AGA Clinical Practice Update on Surgical Risk Assessment and Perioperative Management in Cirrhosis: Expert Review.

Authors:  Patrick G Northup; Lawrence S Friedman; Patrick S Kamath
Journal:  Clin Gastroenterol Hepatol       Date:  2018-09-28       Impact factor: 11.382

4.  Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100 ): influence of hematocrit elevation.

Authors:  G Escolar; A Cases; M Viñas; M Pino; J Calls; I Cirera; A Ordinas
Journal:  Haematologica       Date:  1999-07       Impact factor: 9.941

5.  Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences.

Authors:  Ton Lisman; Robert J Porte
Journal:  Blood       Date:  2010-04-16       Impact factor: 22.113

6.  Changes in health and disease of the metalloprotease that cleaves von Willebrand factor.

Authors:  P M Mannucci; M T Canciani; I Forza; F Lussana; A Lattuada; E Rossi
Journal:  Blood       Date:  2001-11-01       Impact factor: 22.113

7.  Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation.

Authors:  A Dalmau; A Sabaté; F Acosta; L Garcia-Huete; M Koo; T Sansano; A Rafecas; J Figueras; E Jaurrieta; P Parrilla
Journal:  Anesth Analg       Date:  2000-07       Impact factor: 5.108

8.  Transfusion strategies for acute upper gastrointestinal bleeding.

Authors:  Càndid Villanueva; Alan Colomo; Alba Bosch; Mar Concepción; Virginia Hernandez-Gea; Carles Aracil; Isabel Graupera; María Poca; Cristina Alvarez-Urturi; Jordi Gordillo; Carlos Guarner-Argente; Miquel Santaló; Eduardo Muñiz; Carlos Guarner
Journal:  N Engl J Med       Date:  2013-01-03       Impact factor: 91.245

9.  Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis.

Authors:  Lucio Amitrano; Maria Anna Guardascione; Vincenzo Brancaccio; Maurizio Margaglione; Francesco Manguso; Luigi Iannaccone; Elvira Grandone; Antonio Balzano
Journal:  J Hepatol       Date:  2004-05       Impact factor: 25.083

10.  Reduced platelet activation and platelet aggregation in patients with alcoholic liver cirrhosis.

Authors:  Pernille Just Vinholt; Anne-Mette Hvas; Christian Nielsen; Anna Cecilia Söderström; Ulrik Sprogøe; Annette Dam Fialla; Mads Nybo
Journal:  Platelets       Date:  2017-09-12       Impact factor: 3.862

View more
  2 in total

1.  Clinical predictors for thrombus progression in cirrhotic patients with untreated splanchnic vein thrombosis.

Authors:  Hannah McMurry; Jean M G Sabile; Benjamin Elstrott; Boris Chobrutskiy; Ajay Mohinani; Sarah Patel; Sonia Gowda; Kylee Martens; Joseph Shatzel
Journal:  Thromb Res       Date:  2022-05-27       Impact factor: 10.407

Review 2.  Anticoagulation in Cirrhosis: Evidence for the Treatment of Portal Vein Thrombosis and Applications for Prophylactic Therapy.

Authors:  Kylee Martens; Hannah S McMurry; Steven Koprowski; Justine Hum; Jessica Haraga; Janice H Jou; Joseph J Shatzel
Journal:  J Clin Gastroenterol       Date:  2022-04-29       Impact factor: 3.174

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.